Geron corporationGERN.US Overview
US StockHealthcare
(No presentation for GERN)
GERN Overall Performance
GERN AI Analysis & Strategy
GERN Recent Performance
-3.73%
Geron corporation
0.81%
Avg of Sector
-1.14%
S&P500
GERN PowerScanner
GERN Key Information
GERN Valuation Metrics
GERN Earnings Table
GERN Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.